4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach to Chronic Pain
Acquisition combines 4E's innovative MNK inhibitor with Lilly's broad neuroscience capabilities and portfolio AUSTIN, Texas, June 16, 2026 /PRNewswire/ -- 4E Therapeutics, Inc. ("4E"), an Austin-based neuroscience company developing next-generation treatments for chronic pain, today...
Acquisition combines 4E's innovative MNK inhibitor with Lilly's broad neuroscience capabilities and portfolio AUSTIN, Texas, June 16, 2026 /PRNewswire/ -- 4E Therapeutics, Inc. ("4E"), an Austin-based neuroscience company developing next-generation treatments for chronic pain, today...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.